3 completed, 2 terminated, 2 withdrawn, 1 active not recruiting. 9 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 3, Terminated 2, Withdrawn 2, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
Follow Metastatic Malignant Neoplasm in the Bone: new trials by email Literature Review of Metastatic Malignant Neoplasm in the Bone trials Research Report on Metastatic Malignant Neoplasm in the Bone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones Biospecimen Collection, Bone Scan, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2026-10-01 | 2026-08-28 | |
| Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases Computed Tomography, Image Guided Radiation Therapy, Positron Emission Tomography - Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | City of Hope Medical Center | 24 | 2024-08-25 | 2026-10-28 |
| BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors Copanlisib, Elimusertib - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2022-03-22 | 2022-05-27 | |
| Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy Avelumab, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 90 | 2020-10-14 | 2026-10-07 |
| Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers Nivolumab, Ipilimumab, Stereotactic Body Radiation Therapy - Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lung | Phase 1 / Phase 2 | Completed | University of Washington | 20 | 2019-01-15 | 2023-12-29 |
| Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer Laboratory Biomarker Analysis, Pembrolizumab, Ruxolitinib Phosphate - Metastatic Malignant Neoplasm in the Bone, Stage IV Breast Cancer AJCC v6 and v7 | Phase 1 | Completed | Mayo Clinic | 12 | 2017-12-06 | 2024-01-31 |
| Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Carboplatin, Docetaxel, Laboratory Biomarker Analysis - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 / Phase 2 | Terminated | University of Washington | 28 | 2016-02-29 | 2021-10-01 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer Pembrolizumab, pTVG-HP Plasmid DNA Vaccine - Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone | Phase 1 / Phase 2 | Completed | University of Wisconsin, Madison | 66 | 2015-07-01 | 2023-08-01 |
| NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer Contrast-enhanced Magnetic Resonance Imaging, Fludeoxyglucose F-18, Fluorine F 18 Sodium Fluoride - Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone | Phase 1 | Terminated | Stanford University | 4 | 2015-04-01 | 2017-05-30 |
Prostatic Neoplasms (5) · Neoplasm Metastasis (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Lymphatic Metastasis (1) · Salivary Gland Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (9) · Neoplasms by Site (7) · Genital Diseases (5) · Genital Diseases, Male (5) · Genital Neoplasms, Male (5) · Male Urogenital Diseases (5) · Prostatic Diseases (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Neoplastic Processes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Breast Diseases (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2)
Magnetic Resonance Spectroscopy (4) · Specimen Handling (2) · pembrolizumab (2) · BAY 1895344 (1) · CTLA-4 Antigen (1) · Carboplatin (1) · Docetaxel (1) · Fluorodeoxyglucose F18 (1) · Glutamate Carboxypeptidase II (1) · Immunoglobulin G (1) · Ipilimumab (1) · Nivolumab (1) · Pentetic Acid (1) · Photons (1) · Radiosurgery (1)
National Cancer Institute (NCI) (2) · University of Washington (2) · City of Hope Medical Center (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Stanford University (1) · University of Wisconsin, Madison (1)
United States (7)
Andrei Iagaru (1) · Cristina Rodriguez (1) · Donald W Northfelt (1) · Douglas G McNeel, MD PhD (1) · Robert Montgomery (1) · Russell K Pachynski (1) · Timothy A Yap, MD (1) · Yi-Jen Chen (1) · Zin W Myint (1)
PMID 29876010, PMID 30700328, PMID 35277461, PMID 41378786
P30CA015704 (1), P30CA033572 (1), P30CA124435 (1), P50CA097186 (1), UM1CA186689 (1), UM1CA186704 (1), UM1CA186712 (1)